Cargando…
Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911997/ https://www.ncbi.nlm.nih.gov/pubmed/35271563 http://dx.doi.org/10.15585/mmwr.mm7110a2 |
| _version_ | 1784666989278527488 |
|---|---|
| author | Abbott, Andrew Montgomery, Susan P. Chancey, Rebecca J. |
| author_facet | Abbott, Andrew Montgomery, Susan P. Chancey, Rebecca J. |
| author_sort | Abbott, Andrew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8911997 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Centers for Disease Control and Prevention |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89119972022-03-18 Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 Abbott, Andrew Montgomery, Susan P. Chancey, Rebecca J. MMWR Morb Mortal Wkly Rep Full Report Centers for Disease Control and Prevention 2022-03-11 /pmc/articles/PMC8911997/ /pubmed/35271563 http://dx.doi.org/10.15585/mmwr.mm7110a2 Text en https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
| spellingShingle | Full Report Abbott, Andrew Montgomery, Susan P. Chancey, Rebecca J. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 |
| title | Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 |
| title_full | Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 |
| title_fullStr | Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 |
| title_full_unstemmed | Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 |
| title_short | Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021 |
| title_sort | characteristics and adverse events of patients for whom nifurtimox was released through cdc-sponsored investigational new drug program for treatment of chagas disease — united states, 2001–2021 |
| topic | Full Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911997/ https://www.ncbi.nlm.nih.gov/pubmed/35271563 http://dx.doi.org/10.15585/mmwr.mm7110a2 |
| work_keys_str_mv | AT abbottandrew characteristicsandadverseeventsofpatientsforwhomnifurtimoxwasreleasedthroughcdcsponsoredinvestigationalnewdrugprogramfortreatmentofchagasdiseaseunitedstates20012021 AT montgomerysusanp characteristicsandadverseeventsofpatientsforwhomnifurtimoxwasreleasedthroughcdcsponsoredinvestigationalnewdrugprogramfortreatmentofchagasdiseaseunitedstates20012021 AT chanceyrebeccaj characteristicsandadverseeventsofpatientsforwhomnifurtimoxwasreleasedthroughcdcsponsoredinvestigationalnewdrugprogramfortreatmentofchagasdiseaseunitedstates20012021 |